In focus · trending topic

new drug approval

3 stories · following the connections

Adamas Presents Expanded Analysis from the ADS-5102 Open-Label Study Showing Tolerability and Durability out to 88 Weeks

By Nasdaq OMXJun 8, 2017, 8:10 PM UTC

Adamas to Present at the 37th Annual Cowen Health Care Conference

By Nasdaq OMXMar 1, 2017, 7:44 PM UTC

Adamas Outlines Key 2017 Priorities and Highlights 2016 Achievements

By Nasdaq OMXJan 9, 2017, 12:57 AM UTC